Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Georges Abou Rjaili

Cardiovascular Disease Riverside, CA Medical Doctor

NPI 1073896544 CMS profile 679070

4500 Brockton Ave, Ste 203, Riverside, CA 92501

Open in the dashboard

General payments

$16,423

644 records reported · program years 2019–2025

Research payments

$56

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Georges Abou Rjaili of Riverside, CA is reported in the CMS Open Payments database as having received $16,423 across 644 general payments and $56 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,963 93
2024 General $3,545 112
2024 Research $56 1
2023 General $2,056 106
2022 General $2,010 97
2021 General $1,575 66
2020 General $1,399 41
2019 General $3,876 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Georges Abou Rjaili
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Georges Abou Rjaili were reported at $1,963. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Georges Abou Rjaili Cardiovascular Disease median Middle half National median
2019 $3,876 $450 $127–$1,392 $163
2020 $1,399 $242 $77–$751 $114
2021 $1,575 $335 $101–$1,037 $132
2022 $2,010 $395 $121–$1,211 $149
2023 $2,056 $443 $136–$1,283 $160
2024 $3,545 $450 $136–$1,323 $164
2025 $1,963 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,140 23 payments
  2. Novartis Pharmaceuticals Corporation $1,722 143 payments
  3. Abiomed $1,563 33 payments
  4. Abbott Laboratories $1,240 17 payments
  5. Merck Sharp & Dohme Corporation $908 42 payments
  6. AstraZeneca Pharmaceuticals LP $876 42 payments
  7. E.R. Squibb & Sons, L.L.C. $747 31 payments
  8. Alnylam Pharmaceuticals Inc. $691 21 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $648 30 payments
  10. Amgen Inc. $630 36 payments
  11. Other $5,259 226 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,491 630 payments
  2. Travel and Lodging $1,845 7 payments
  3. Education $86 7 payments
Products named General payments · program years 2019–2025
  1. COREVALVE EVOLUT R $1,797 18 payments
  2. Impella $1,518 32 payments
  3. Mitra Clip system $1,130 12 payments
  4. VERQUVO $1,085 51 payments
  5. LEQVIO $1,028 76 payments
  6. NEXLETOL $611 37 payments
  7. Repatha $547 32 payments
  8. CoreValve Evolut $535 6 payments
  9. ENTRESTO $527 53 payments
  10. JARDIANCE $467 21 payments
  11. Other $8,572 393 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $56 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

4,107

Median for Cardiology: 2,533

Drug cost

$1,208,793

Median for Cardiology: $485,213

Branded share of claims

38.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 257 $221,501
Brilinta Ticagrelor Brand 196 $162,003
Entresto Sacubitril/Valsartan Brand 142 $153,239
Eliquis Apixaban Brand 134 $152,802
Camzyos Mavacamten Brand 12 $100,706
Nexlizet Bempedoic Acid/Ezetimibe Brand 75 $51,092
Jardiance Empagliflozin Brand 38 $47,733
Praluent Pen Alirocumab Brand 51 $41,806
Farxiga Dapagliflozin Propanediol Brand 32 $38,014
Vascepa Icosapent Ethyl Brand 55 $30,606

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$921,590

Of which drugs: $486,057

Medicare patients

554

Average age 76

Services billed

54,740

290 women, 264 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 71%
Arthritis 51%
Diabetes 50%
Chronic kidney disease 42%
Heart failure 39%
Atrial fibrillation 31%
Depression 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 103 51,404 $486,045

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $336
$336 — 51,404
VERQUVO
  • Merck Sharp & Dohme Corporation $202
$202 16 —
WAINUA
  • AstraZeneca Pharmaceuticals LP $165
$165 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $153
$153 38 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $141
$141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record